Loryna Kit
Product Images NDC 70700-114

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Loryna (NDC 70700-114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed, Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Loryna Carton

LORYNA 3 mg/0.02 mg Drospirenone and Ethinyl Estradiol Tablets USP kit by Xiromed, LLC. The packaging indicates a 28-day regimen with 3 units of 3x28 tablet blister cards. The box features a white and pink design with the proprietary and generic names prominently displayed, along with the dosage strength and labeler information.*

FDA Label Image

Loryna Figure 01

A forest plot chart depicting various study results on VTE (venous thromboembolism) risk associated with Drospirenone and Ethinyl Estradiol relative to LNG-containing combined oral contraceptives. The studies are grouped as prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic case-only, showing hazard ratios, rate ratios, and odds ratios with confidence intervals along a logarithmic scale from 0.1 to 10.*

FDA Label Image

Loryna Figure 02

A horizontal bar chart illustrating the number of women with a blood clot per 10,000 women years (WY) across four categories: Non-Pregnant Non-COC user, COC-User, Pregnancy, and Postpartum (12 weeks only). Each bar is divided to show a range of values for blood clot occurrences, increasing from top to bottom.*

FDA Label Image

Loryna Figure 03

Chemical structures of Drospirenone and Ethinyl Estradiol, the active ingredients in LORYNA. The diagrams show the molecular arrangements including rings, bonds, and functional groups typical for these steroid compounds.*

FDA Label Image

Loryna Figure 04

An illustration showing a vertical arrow indicating pregnancy rates per 100 women per year, from 'fewer pregnancies' at the top to 'more pregnancies' at the bottom. To the right are boxes listing birth control methods corresponding to each level of pregnancy rates: at the top, implants, injections, intrauterine devices, and sterilization; below, birth control pills, skin patch, and vaginal ring with hormones; further down, condoms and diaphragm; then no sex during fertile days, spermicide, and withdrawal; and at the bottom, no birth control.*

FDA Label Image

Loryna Figure 05

A horizontal bar chart comparing the likelihood of developing a serious blood clot among different groups: Non-Pregnant Non-COC users, COC users, Pregnant women, and women in the postpartum period (12 weeks only). The chart shows ranges of the number of women with a blood clot out of 10,000 women years, with postpartum women having the highest risk (40 to 65), followed by pregnancy (5 to 20), COC users (3 to 9), and non-pregnant non-COC users (1 to 5).*

FDA Label Image

Loryna Figure 06

A forest plot showing effect estimates comparing ever and current use of combined oral contraceptives (COC) versus never use across multiple studies. The x-axis depicts effect estimates from -1.5 to 2.0. Study names and years are listed on the left, with corresponding odds ratios (OR), relative risks (RR), and hazard ratios (HR) with confidence intervals on the right. The plot displays point estimates with horizontal confidence intervals for each study.*

FDA Label Image

Loryna New Blister

Illustration of the LORYNA kit dosing schedule for Drospirenone and Ethinyl Estradiol Tablets, USP 3 mg/0.02 mg. It shows a four-week cycle with circles representing daily doses arranged by day of the week from Sunday to Saturday, starting at Week 1 through Week 4. Week 4 has shaded circles indicating inactive or placebo pills, with arrows guiding the tablet sequence.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.